Abstract
To determine whether psychiatrically stable patients with a history of drug-induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on-going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses.
References
Jun 1, 1978·The American Journal of Psychiatry·C MoskovitzH L Klawans
Apr 1, 1995·Neurology·C G Goetz, G T Stebbins
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Dec 1, 1996·Archives of Neurology·J R Sanchez-RamosG W Paulson
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezM Rosenfeld
Mar 29, 2000·Brain : a Journal of Neurology·G FénelonM Ziégler
Apr 6, 2000·Neurology·W J WeinerL M Shulman
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezB P Abbott
Sep 20, 2000·Neurology·H H Fernandez
Dec 12, 2001·Neurology·C G GoetzA B Stemer
Jun 11, 2003·Neurology·S A FactorUNKNOWN Parkinson Study Group
Jun 20, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hubert H FernandezJoseph H Friedman
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Janet RomrellMichael S Okun
Citations
Jun 27, 2006·Journal of Neurologic Physical Therapy : JNPT·Lee E Dibble, Mark Lange
Oct 8, 2005·Postgraduate Medical Journal·B R ThanviD P Harsh
Jul 31, 2008·Drugs & Aging·Laura B Zahodne, Hubert H Fernandez
Dec 7, 2007·Expert Review of Neurotherapeutics·Marco OnofrjLaura Bonanni
Mar 22, 2006·Expert Opinion on Investigational Drugs·Kelvin L Chou, Hubert H Fernandez
Jun 16, 2006·Acta Psychiatrica Scandinavica·J Moncrieff
Jan 15, 2015·Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater·Jacopo Vittoriano BizzarriHans Peter Kapfhammer
Aug 30, 2008·Journal of Psychopharmacology·A J Goudie, J C Cole
Oct 24, 2017·Clinical Neuropharmacology·Joseph BergmanChanoch Miodownik
Feb 3, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Bernard RavinaChristopher Goetz
Mar 5, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Spiridon Papapetropoulos, Deborah C Mash
Mar 20, 2013·Journal of Psychiatric Practice·Rosa Quelhas
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezChristopher G Goetz
Apr 15, 2016·British Journal of Clinical Pharmacology·Amy T PageChristopher D Etherton-Beer
Apr 2, 2008·CNS Spectrums·Laura B Zahodne, Hubert H Fernandez
Jul 4, 2006·CNS Spectrums·Leora L BorekJoseph H Friedman
Jun 26, 2021·BMC Neurology·Thanh Phuong Pham NguyenAllison W Willis
Feb 4, 2010·Parkinsonism & Related Disorders·Josè Martin Rabey